Dual inhibition of the MAPK pathway by combination targeted therapy: a phase I trial of sorafenib (SOR) and erlotinib (ERL) in advanced solid tumors

被引：5
|
作者：
Duran, I.
Hotte, S.
Chen, E.
Hirte, H.
MacLean, M.
Turner, S.
Pond, G.
Wright, J.
Dancey, J.
Siul, L.
机构：
[1] Princess Margaret Hosp Phase II Consortium, Toronto, ON, Canada
[2] Natl Canc Inst, Bethesda, MD USA
来源：
EJC SUPPLEMENTS | 2006年 / 4卷 / 12期
关键词：
D O I：
10.1016/S1359-6349(06)70555-9
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
550
引用
收藏
页码：167 / 167
页数：1
相关论文
共 50 条
  • [31] Gemcitabine and carboplatin combination in advanced solid tumors: A phase I trial.
    Tassinari, D
    Pasini, G
    Arcangeli, V
    Panzini, I
    Drudi, G
    Gianni, L
    Oliverio, G
    Sartori, S
    Fochessati, F
    ANNALS OF ONCOLOGY, 2000, 11 : 141 - 141
  • [32] A Phase I Trial of Bexarotene in Combination With Docetaxel in Patients With Advanced Solid Tumors
    Malik, Shakun M.
    Collins, Brian
    Pishvaian, Michael
    Ramzi, Pari
    Marshall, John
    Hwang, Jimmy
    CLINICAL LUNG CANCER, 2011, 12 (04) : 231 - 236
  • [33] Bortezomib in combination with celecoxib in patients with advanced solid tumors: a phase I trial
    Hayslip, John
    Chaudhary, Uzair
    Green, Mark
    Meyer, Mario
    Dunder, Steven
    Sherman, Carol
    Salzer, Shanta
    Kraft, Andrew
    Montero, Alberto J.
    BMC CANCER, 2007, 7 (1)
  • [34] A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors
    Schelman, William
    Morgan-Meadows, Sherry
    Bailey, Howard
    Holen, Kyle
    Thomas, James P.
    Eickhoff, Jens
    Brandon, Heidi
    Oliver, Kate
    Alberti, Dona
    Wilding, George
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (04) : 727 - 733
  • [35] A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
    Yannis Metaxas
    Carmen Kahatt
    Vicente Alfaro
    Salvador Fudio
    Ali Zeaiter
    Ruth Plummer
    Cristiana Sessa
    Roger Von Moos
    Martin Forster
    Anastasios Stathis
    Investigational New Drugs, 2022, 40 : 91 - 98
  • [36] Phase I trial of bortezomib in combination with ocetaxel in patients with advanced solid tumors
    Messersmith, WA
    Baker, SD
    Lassiter, L
    Sullivan, RA
    Dinh, K
    Almuete, VI
    Wright, JJ
    Donehower, RC
    Carducci, MA
    Armstrong, DK
    CLINICAL CANCER RESEARCH, 2006, 12 (04) : 1270 - 1275
  • [37] A phase I trial of lurbinectedin in combination with cisplatin in patients with advanced solid tumors
    Metaxas, Yannis
    Kahatt, Carmen
    Alfaro, Vicente
    Fudio, Salvador
    Zeaiter, Ali
    Plummer, Ruth
    Sessa, Cristiana
    Von Moos, Roger
    Forster, Martin
    Stathis, Anastasios
    INVESTIGATIONAL NEW DRUGS, 2022, 40 (01) : 91 - 98
  • [38] Phase I trial of combination becatecarin and oxaliplatin in patients with advanced solid tumors
    Manda, S.
    Mauser, C.
    Bokar, J.
    Cooney, M.
    Brell, J.
    Krishnamurthi, S.
    Savvides, P.
    Ivy, P.
    Remick, S.
    Dowlati, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [39] Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial
    Nardo, Mirella
    Gouda, Mohamed A.
    Reilley, Matthew J.
    Biter, Amadeo B.
    Lim, Joann
    Bean, Stacie A.
    Nguyen, Ly M.
    Bhosale, Priya R.
    Ager, Casey R.
    Couillault, Coline A.
    Piha-Paul, Sarina A.
    Fu, Siqing
    Tsimberidou, Apostolia M.
    Yap, Timothy A.
    Naing, Aung
    Rodon, Jordi
    Subbiah, Vivek
    Karp, Daniel D.
    Curran, Michael A.
    Hong, David S.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2025, 8 (02) : 89 - 98
  • [40] CTEP #8850: A phase I trial of riluzole and sorafenib in patients with advanced solid tumors.
    Spencer, Kristen Renee
    Mehnert, Janice M.
    Tan, Antoinette R.
    Moss, Rebecca Anne
    Levinson, Kelly
    Stein, Mark N.
    Huzzy, Lien
    Kane, Michael P.
    Gibbon, Darlene
    Wright, John Joseph
    Aisner, Joseph
    DiPaola, Robert S.
    Chen, Suzie
    Wen, Yvonne
    Goydos, James
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345